GISTs are tumors of the gastrointestinal stroma which, although rare, are the most common mesenchymal neoplasms of the digestive tract. They are most common in the stomach and small intestine, in patients aged between 50 and 70 years. The definitive diagnosis is established with immunohistochemistry (CD117), and the risk of postoperative recurrence should be estimated. Studies relate small intestine’s lesions with greater aggressiveness; however, more recent studies emphasize mitotic index and lesion size.
The clinical case is that of a 53-year-old woman with a stage TNM IIIb, AFIP 6b gastric GIST. In 2013, she underwent a sleeve gastrectomy followed by the daily administration of Imatinib (400mg). After 3 years of adjuvant therapy, she stopped treatment. In May 2017, in a follow-up CT-scan, a solid, heterogeneous 6.7cm lesion appeared in the left hypochondrium, separated from the metal suture, invading the lower pole of the spleen, with no evidence of adenopathies or free liquid.
Surgical resection was planned. A splenectomy with distal pancreatectomy, documented in the video, was performed with no complications. The histological examination confirmed a 5.8cm tumor implant, located in the splenic cord, compatible with GIST recurrence (>50 mitoses/50 fields, free margins, prognostic group 6b).